Genomic Intelligence AI
Genome-scale AI models for disease risk prediction, heritability explanation, and genomic edits.
Website: https://genomicintelligence.ai/
Cover Block
Public sources
| Attribute | Value |
|---|---|
| Name | Genomic Intelligence AI |
| Tagline | Genome-scale AI models for disease risk prediction, heritability explanation, and genomic edits. |
| Stage | Pre-Seed |
| Industry | Deeptech |
| Technology | AI / Machine Learning |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
Links
Public sources
Executive Summary
Public sources Genomic Intelligence AI is an early-stage deeptech startup applying long-context foundation models to whole-genome analysis, a technical approach that could unlock more comprehensive disease risk prediction and genetic editing if the science holds. The company's public emergence in late September 2026 presents a rare, early look at a team attempting to scale AI architectures to the full complexity of genomic data, a frontier that has historically been constrained by computational limits on sequence length [Genomic Intelligence, September 2026]. The founding premise rests on moving beyond analyzing short DNA snippets or individual variants, instead modeling entire genomes and multi-omics datasets to explain heritability and design actionable edits [Genomic Intelligence, September 2026].
Key figures associated with the project bring relevant expertise from AI research, genomics, and large-scale infrastructure, though their precise roles and the founding entity's structure are not yet publicly formalized. Julia Kiseleva and Benjamin Fishman are cited for product vision and wet-lab validation, respectively, while Mikhail Burtsev is noted for work on ultra-long-context models [Genomic Intelligence, September 2026]. The involvement of advisors like Microsoft's Eric Horvitz and Cerebras's Natalia Vassilieva points to strategic connections in AI-for-health and high-performance computing, but does not constitute operational validation.
No funding rounds, a business model, or customer deployments have been announced, placing the company in a pre-seed, concept-validation phase. The immediate investor watch points are straightforward: securing institutional capital to fund model training on proprietary genomic data, transitioning from a technical blog to a demonstrable product wedge, and clarifying the commercial path between academic research and a scalable enterprise. Over the next 12-18 months, evidence of a closed seed round and a published research benchmark would signal credible momentum.
Lightly corroborated -- Core technical claims are sourced solely from the company's website; team member backgrounds are partially corroborated by independent LinkedIn profiles.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Pre-Seed |
| Industry / Vertical | Deeptech |
| Technology Type | AI / Machine Learning |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
How the Company Got Here
Public sources
Genomic Intelligence AI presents as a deeptech research venture, emerging publicly in the second half of 2026 with a focus on applying large-scale AI to whole-genome data. The company's founding date, headquarters location, and legal structure are not disclosed in its public materials [Genomic Intelligence, September 2026]. Its operational history appears nascent, with the primary verifiable milestone being the launch or substantial update of its public-facing website and technical blog in September 2026 [Genomic Intelligence, September 2026]. This digital presence articulates the company's core technical ambition but does not list prior product releases, customer engagements, or institutional funding events.
The team composition, as described on the company site, blends individuals with backgrounds in AI research, genomics, and computational infrastructure. While roles are outlined for product vision, wet-lab validation, and model architecture, the site does not formally distinguish between founders, employees, and advisers [Genomic Intelligence, September 2026]. External LinkedIn profiles for some named individuals provide partial, independent corroboration of their professional backgrounds in AI and machine learning [Julia Kiseleva - Stealth | LinkedIn, 2026] [Ben Fishman - Bar-Ilan University | LinkedIn, 2026].
Lightly corroborated -- Key company descriptors (stage, team focus) are from a single company source; individual professional backgrounds have partial independent corroboration via LinkedIn. Foundational facts like incorporation date and location remain unconfirmed.
Product and Technology
Sources and analysis The company's technical proposition centers on applying large-scale AI architectures directly to genomic data, a field where computational methods have historically been constrained by sequence length. According to its website, Genomic Intelligence AI is developing "ultra-long-context genomic foundation models" designed to process whole-genome and multi-omics data [Genomic Intelligence, September 2026]. The stated goals for these models are to predict disease risk, explain the heritability of complex traits, and design actionable genetic edits, positioning the technology as a tool for both discovery and intervention [Genomic Intelligence, September 2026].
A key differentiator, as framed by the company, is the focus on whole-genome scale analysis. This suggests a move away from methods that examine individual variants or short sequences in isolation, aiming instead to capture the broader genomic context that may influence biological outcomes [Genomic Intelligence, September 2026]. The platform architecture reportedly includes agentic workflows that integrate these specialized genomic models with established bioinformatics tools, a detail corroborated by a team member's LinkedIn profile [Veniamin Fishman - AIRI | LinkedIn, 2026]. This points to an ambition to build not just a model but an automated system for genomic analysis.
Single unverified source -- Core product claims are sourced solely from the company's website and a team member's social profile; no independent technical validation or customer deployment evidence is publicly available.
Where the Demand Sits
Sources and analysis The market for AI-driven genomic analysis is being reshaped by a convergence of technical breakthroughs and sustained investment in biological data generation, creating a window for new approaches that can process information at the scale of an entire genome.
Third-party market sizing specifically for genome-scale AI platforms is not yet established in public reports. Analysts have, however, quantified the broader adjacent markets that this technology aims to penetrate. The global market for AI in genomics was valued at $1.2 billion in 2023 and is projected to grow at a compound annual rate of approximately 45% through 2030, reaching an estimated $16 billion [Grand View Research, 2024]. This growth is anchored in the expanding market for next-generation sequencing, which itself is forecast to exceed $40 billion by 2030 [Precedence Research, 2024]. These figures provide an analogous context for the potential addressable market, though the specific wedge for whole-genome foundation models represents a narrower, high-value segment within it.
Demand is propelled by several identifiable tailwinds. The cost of sequencing a human genome has fallen below $1,000, driving an exponential increase in available genomic data [NHGRI, 2024]. Simultaneously, the architecture of large language models has demonstrated an ability to process extremely long sequences of text, a capability that researchers are now applying to the billion-base-pair sequences of DNA [Nature Biotechnology, 2025]. This technical parallel suggests that AI models capable of contextualizing variants across an entire genome, rather than in isolation, could unlock more accurate predictions for polygenic disease risk and complex trait heritability. The commercial pull comes from pharmaceutical R&D, where target identification and patient stratification are multibillion-dollar cost centers, and from a growing direct-to-consumer and clinical diagnostics sector seeking more comprehensive risk reports.
Key adjacent and substitute markets define the competitive landscape. The primary substitute remains traditional statistical genetics and genome-wide association studies (GWAS), which are well-established but limited in their ability to model high-order interactions. Adjacent markets include variant interpretation databases (e.g., ClinVar) and bioinformatics software suites (e.g., those from Illumina or Qiagen), which are workflow tools rather than predictive engines. The regulatory environment is a material force, particularly in the United States and European Union where clinical claims based on algorithmic predictions fall under FDA and EU IVDR scrutiny, respectively. Macro forces are positive, with continued public and private investment in precision medicine initiatives, but also introduce risk through potential shifts in data privacy laws (like GDPR) that govern the use of human genomic information.
AI in Genomics (2023) | 1.2 | $B
Next-Gen Sequencing (2030 est.) | 40 | $B
AI in Genomics (2030 est.) | 16 | $B
The projected growth rates indicate a sector where total addressable market expansion is itself a catalyst for new entrants. The critical diligence question is not whether the market is large, but whether a new architectural approach can capture meaningful share from entrenched analytical methods and existing AI point solutions.
Lightly corroborated -- Market sizing relies on third-party analyst reports for adjacent sectors; specific sizing for the company's niche is not publicly available.
Competitive Landscape
Sources and analysis Genomic Intelligence AI's competitive position is currently defined by its early-stage research focus on whole-genome foundation models, a technical ambition that places it in a narrow, high-risk segment of the computational biology market.
The company's public positioning, as of its September 2026 website launch, targets a specific technical gap: applying ultra-long-context AI models to analyze entire genomes and multi-omics datasets, rather than focusing on short sequences or known variants [Genomic Intelligence, September 2026]. This approach contrasts with established market segments. Incumbent bioinformatics platforms like Illumina's DRAGEN or Qiagen's CLC Genomics Workbench offer validated, production-ready pipelines for variant calling and annotation but are not built on foundation models. Emerging AI-native challengers, such as those leveraging large language models for genomic interpretation, often work on curated gene panels or known variant databases, not raw whole-genome data. Adjacent substitutes include large pharmaceutical companies' internal AI research teams and academic consortia, which possess deep domain expertise and proprietary data but lack the singular product focus of a startup.
Where the subject may have a defensible edge today lies in its stated technical architecture and the specialized backgrounds of its named contributors. The involvement of individuals with published expertise in memory architectures for long-context models and large-scale machine learning infrastructure suggests a talent concentration on the core technical hurdle [Genomic Intelligence, September 2026]. This edge is highly perishable, however. It is predicated on the team's ability to translate research into a functional, scalable product before well-funded competitors,from both the tech sector (e.g., Google DeepMind's AlphaFold team, NVIDIA's BioNeMo platform) and the biopharma world,allocate similar resources to the same problem. Without secured intellectual property, exclusive data partnerships, or a commercial product, this talent-based moat is fragile.
The company is most exposed on commercial and validation fronts. It lacks a publicly articulated path to market, customer case studies, or any disclosed partnerships with entities that could provide the massive, high-quality genomic datasets required to train its proposed models [Genomic Intelligence, September 2026]. A named competitor with a significant advantage would be a company like Genomenon, which has an established commercial business aggregating curated genomic literature to aid in variant interpretation for clinical labs, demonstrating a clear revenue model and customer base [Perplexity Sonar Pro Brief]. Genomic Intelligence AI's pure research focus also leaves it vulnerable to adjacent tech giants that could decide to open-source a foundational genomic model, effectively commoditizing the core layer the company is trying to build.
The most plausible 18-month competitive scenario hinges on proof-of-concept validation. The winner in this segment will be the first entity to publicly demonstrate that a whole-genome foundation model can predict a polygenic disease risk or explain non-coding heritability with accuracy meaningfully beyond existing statistical methods, and do so on a dataset of significant scale. If Genomic Intelligence AI can achieve such a milestone and couple it with a preprint or partnership with a major research hospital, it could secure the seed funding and attention needed to advance. The loser in this scenario would be any team that remains in stealth without a tangible validation output, as investor and partner interest will likely consolidate around the first mover to show credible, peer-reviewable results.
Lightly corroborated -- Competitive analysis is based on the company's stated technical goals and a high-level mapping of known market segments. The absence of named, direct competitors in the sources limits specificity; the assessment of adjacent players and scenarios is analytical.
Opportunity
Public sources The prize for any company that can reliably translate whole-genome data into actionable health predictions is a fundamental reordering of the biopharma and clinical diagnostics markets, measured in tens of billions of dollars in annual value creation.
The headline opportunity is to become the foundational AI layer for genomic interpretation, a category-defining platform that pharmaceutical researchers, clinical labs, and eventually healthcare providers use to move from raw sequence data to prioritized therapeutic targets and patient risk profiles. This outcome is reachable not because Genomic Intelligence has achieved it, but because the technical approach it describes directly addresses a persistent bottleneck. Current genomic analysis is often siloed, focusing on individual variants or short sequences, which can miss complex polygenic interactions and non-coding region effects [Genomic Intelligence, September 2026]. A model capable of analyzing an entire genome as a single, ultra-long-context data object could, in theory, capture these systemic patterns. The company's stated intent to build agentic workflows that combine specialized models with established bioinformatics tools suggests a path to integration, not just raw model performance [Veniamin Fishman - AIRI | LinkedIn, 2026]. If the underlying science proves out, the platform that first delivers reliable, whole-genome-scale predictions would be positioned as a default infrastructure component for a data-intensive industry.
Growth scenarios outline specific paths from technical validation to commercial scale. The available public evidence supports the plausibility of the underlying technical direction, though not the company's specific execution.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Research Platform Adoption | The company's models become the standard tool for early-stage therapeutic target discovery within academic and biotech R&D. | A published validation study in a high-impact journal demonstrating superior prediction accuracy for a complex disease phenotype. | The biopharma industry's R&D process is heavily driven by published, peer-reviewed science. A single compelling validation could drive adoption as a research tool, similar to how AlphaFold2 was adopted [Nature, 2021]. |
| Embedded API for Clinical Labs | The company's risk prediction models are licensed and embedded into the analysis pipelines of large-scale clinical genetic testing providers. | A partnership with a major diagnostic lab to co-develop a specific test for a high-prevalence condition like cardiovascular disease. | Diagnostic labs constantly seek more predictive algorithms to differentiate their reports. Licensing AI from a specialized provider is a established commercial model in adjacent spaces like medical imaging. |
What compounding looks like in this field is a data and validation flywheel. Early adopters in research generate novel biological insights and, potentially, proprietary datasets from experiments designed using the platform. These new datasets can be used to retrain and improve the core models, increasing their predictive power. Improved models attract more researchers and larger commercial partners, who in turn generate more diverse data and validation cases. This cycle creates a moat: the model with the most diverse training data and the broadest set of real-world validation studies becomes the hardest to displace. The company's blog mentions using "distribution to discover genomic workflows," which hints at an understanding of this iterative learning loop, though it remains a stated ambition rather than an observed result [Genomic Intelligence, September 2026].
The size of the win can be framed by looking at the value captured by companies that established foundational layers in adjacent data-driven life science markets. For example, Illumina's sequencing instruments became the default platform for generating genomic data, commanding a market capitalization that has ranged between $20 billion and $75 billion over the past five years. While Genomic Intelligence operates in software interpretation, not hardware, the comparable suggests the scale of value creation possible for a company that defines a critical, hard-to-replicate layer in the genomics value chain. In a scenario where it becomes the dominant AI platform for therapeutic target discovery, capturing even a single-digit percentage of the global pharmaceutical R&D budget,which exceeds $200 billion annually,would represent a multi-billion dollar annual revenue opportunity. This is a scenario-based illustration of potential, not a forecast for this specific company.
Lightly corroborated -- The opportunity analysis is built on the company's stated technical goals and the well-documented needs of the genomics market, but lacks independent validation of the company's progress toward those goals.
Sources
Public sources
[Genomic Intelligence, September 2026] Genomic Intelligence , Genome-scale AI for biology | https://genomicintelligence.ai/
[Veniamin Fishman - AIRI | LinkedIn, 2026] Veniamin Fishman LinkedIn Profile | https://www.linkedin.com/in/veniamin-fishman/
[Julia Kiseleva - Stealth | LinkedIn, 2026] Julia Kiseleva LinkedIn Profile | https://www.linkedin.com/in/julia-kiseleva-24842710/
[Ben Fishman - Bar-Ilan University | LinkedIn, 2026] Ben Fishman LinkedIn Profile | https://www.linkedin.com/in/ben--fishman/
[Grand View Research, 2024] AI in Genomics Market Size Report | https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-ai-in-genomics-market-report
[Precedence Research, 2024] Next Generation Sequencing Market Report | https://www.precedenceresearch.com/next-generation-sequencing-market
[NHGRI, 2024] The Cost of Sequencing a Human Genome | https://www.genome.gov/about-genomics/fact-sheets/Sequencing-Human-Genome-cost
[Nature Biotechnology, 2025] Large language models for genomics | https://www.nature.com/articles/s41587-024-02429-3
[Nature, 2021] Highly accurate protein structure prediction with AlphaFold | https://www.nature.com/articles/s41586-021-03819-2
Articles about Genomic Intelligence AI
- Genomic Intelligence AI's Foundation Models Take the Whole Genome as a Single Prompt — The early-stage team, with advisors from Microsoft and Cerebras, is betting that long-context AI can predict disease risk and design genetic edits.